Johnson & Johnson s Talc Lawsuits Are Fueling Skepticism of Its COVID Vaccine
On 3/9/21 at 7:15 AM EST
Concern over previous Johnson & Johnson lawsuits is helping drive vaccine alarmism and skepticism,
Newsweek analysis has found. Since Johnson & Johnson s one-shot vaccine was approved on February 27 for emergency use it has been critiqued for its perceived shortcomings in efficacy.
More than one in four people who do not intend to get vaccinated cited concerns about drug companies, according to a February 26 CBS/YouGov poll. But brand hesitancy has also reached those who do wish to be vaccinated.
Hundreds of social media posts have linked the vaccine with allegations the company s
Calliditas strengthens its US Commercial and Medical Affairs Organization
News provided by
Share this article
STOCKHOLM, March 8, 2021 /PRNewswire/
Calliditas Therapeutics AB (publ) ( Calliditas ) today announced the appointment of three industry veterans: Warren Brooks, PhD, as Vice President of US Medical Affairs, Teona Johnson as Head of US Marketing and David Ferraro as Head of US Sales.
Calliditas Therapeutics has bolstered its US organization with three pharmaceutical veterans as it moves towards the potential commercialization of its lead product candidate, Nefecon. This is an important step on our continued path to deliver on our promise to build a center of excellence in the US. This shows our long term commitment to building an organization focused on the commercialization of orphan drugs to address unmet medical needs , said Renee Aguiar-Lucander, CEO of Calliditas.
Coronavirus Briefing: What Happened Today nytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nytimes.com Daily Mail and Mail on Sunday newspapers.
How the Stock Market Is Responding to President Joe Biden — And What That Means for Your Investments yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.